Consensus PTC Therapeutics, Inc. Berne S.E.

Stocks

P91

US69366J2006

Pharmaceuticals

Delayed Berne S.E.			5-day change	1st Jan Change
- ^CHF	-.--%		-.--%	-

09-15	PTC Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 09:15 AM
08-24	Ptc Therapeutics Announces New Sephience Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as Well as Consistent Favorable Safety Profile	CI

9.QJk3LY1sqBZ2zEWooMru68hiu7LAjoU_P9ey19Aik5w.LsNWfsQI8WQcvyLj4ajevZBSiMaE67YSSq_5hb9Vo_sP7FVv9QT4fy6HCA~a912489be6dd6fa1740fff3892c9123c

Analysts' recommendations: PTC Therapeutics, Inc.

07-27	PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says	MT
07-07	RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating	MT
06-09	PTC Therapeutics Shares Rise After Upgrade From Citigroup	MT
06-09	Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76	MT
05-08	TD Cowen Upgrades PTC Therapeutics to Buy From Hold, Adjusts Price Target to $90 From $75	MT
04-07	RBC Adjusts Price Target on PTC Therapeutics to $81 From $82, Maintains Sector Perform Rating	MT
02-23	Morgan Stanley Lifts Price Target on PTC Therapeutics to $92 From $90, Keeps Overweight Rating	MT
02-20	RBC Cuts Price Target on PTC Therapeutics to $82 From $87, Keeps Sector Perform Rating	MT
01-08	RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating	MT
12-02	PTC Therapeutics Shares Drop After RBC Downgrade	MT
12-01	RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82	MT
11-05	RBC Capital Adjusts PTC Therapeutics Price Target to $82 From $70, Maintains Outperform Rating	MT
08/10/25	RBC Raises Price Target on PTC Therapeutics to $70 From $63, Keeps Outperform Rating	MT
08/08/25	RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating	MT
08/08/25	Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating	MT
29/07/25	UBS Adjusts Price Target on PTC Therapeutics to $80 From $71, Maintains Buy Rating	MT
29/07/25	Truist Raises Price Target on PTC Therapeutics to $86 From $80, Keeps Buy Rating	MT
04/06/25	RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating	MT
09/05/25	BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55	MT
07/05/25	Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50	MT
05/05/25	RBC Capital Adjusts PTC Therapeutics Price Target to $57 From $65, Maintains Outperform Rating	MT
03/04/25	RBC Lifts Price Target on PTC Therapeutics to $65 From $64, Keeps Outperform Rating	MT
28/02/25	RBC Capital Adjusts PTC Therapeutics Price Target to $64 From $63, Maintains Outperform Rating	MT
18/02/25	RBC Capital Adjusts PTC Therapeutics Price Target to $63 From $60, Maintains Outperform Rating	MT
07/01/25	RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating	MT

More recommendations

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
ELI LILLY AND COMPANY		+12.14%
JOHNSON & JOHNSON		+2.67%
ABBVIE INC.		+5.09%
ROCHE HOLDING AG		+3.29%
NOVARTIS AG		+6.25%
ASTRAZENECA PLC	-	+28.98%
AMGEN INC.		-4.14%
GILEAD SCIENCES, INC.		+5.99%
NOVO NORDISK A/S		+21.56%
Average		+9.09%
Weighted average by Cap.		+8.55%